Merck KGaA (FRA:MRK) has been assigned a €95.00 ($117.28) price target by stock analysts at JPMorgan Chase & Co. in a report issued on Monday. The firm currently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 13.77% from the company’s previous close.
Several other research firms have also issued reports on MRK. UBS Group set a €120.00 ($148.15) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Monday, January 8th. Kepler Capital Markets set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Monday, November 6th. Independent Research set a €103.00 ($127.16) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday, November 9th. Warburg Research set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, Berenberg Bank set a €116.00 ($143.21) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a report on Thursday, November 9th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of €107.57 ($132.80).
Merck KGaA (FRA MRK) opened at €83.50 ($103.09) on Monday. Merck KGaA has a 52-week low of €80.50 ($99.38) and a 52-week high of €115.00 ($141.98). The stock has a market cap of $10,820.00 and a PE ratio of 19.56.
WARNING: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/21/merck-kgaa-mrk-pt-set-at-95-00-by-jpmorgan-chase-co.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.